PGNY vs SYK: fair value comparison
Progyny, Inc. and Stryker Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, SYK currently sits closer to the top of our discount ranking.
| PGNY | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $25.66 | $275.56 |
| 12-month range | $16.86–$31.53 | $294.73–$387.02 |
| Sector rank | #21 of 113 Healthcare | #18 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: PGNY fair value analysis · SYK fair value analysis